Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H21N |
Molecular Weight | 239.3553 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CC1=CC=CC=C1)N(C)CC2=CC=CC=C2
InChI
InChIKey=YXKTVDFXDRQTKV-HNNXBMFYSA-N
InChI=1S/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1
Benzphetamine is a sympathomimetic agent with properties similar to dextroamphetamine. It is used in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Presumably, benzphetamine produces its effects through mechanisms similar to amphetamine via induces synaptic vesicular amine transporter, but precise mechanism of action of benzphetamine is not known.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1893 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | BENZPHETAMINE HYDROCHLORIDE Approved UseBenzphetamine hydrochloride tablets are indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Benzphetamine hydrochloride tablets are indicated for use as monotherapy only. Launch Date2006 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.9 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8787790 |
10 mg/kg 1 times / day multiple, intraperitoneal dose: 10 mg/kg route of administration: Intraperitoneal experiment type: MULTIPLE co-administered: |
BENZPHETAMINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13% |
BENZPHETAMINE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Other AEs: Gastrointestinal signs and symptoms, Dizziness... Other AEs: Gastrointestinal signs and symptoms (5 patients) Sources: Dizziness (4 patients) Constipation (2 patients) Nervousness (5 patients) Pruritus (1 patient) Dry mouth (3 patients) Chest pain (1 patient) Headache (1 patient) Malaise (1 patient) Fatigue (1 patient) Appetite disorder (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Appetite disorder | 1 patient | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Chest pain | 1 patient | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Fatigue | 1 patient | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Headache | 1 patient | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Malaise | 1 patient | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Pruritus | 1 patient | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Constipation | 2 patients | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Dry mouth | 3 patients | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Dizziness | 4 patients | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Gastrointestinal signs and symptoms | 5 patients | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Nervousness | 5 patients | 80 mg 3 times / day multiple, oral (max) Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 54 n = 20 Health Status: unhealthy Condition: Obesity Age Group: 54 Sex: F Population Size: 20 Sources: |
Sample Use Guides
Dosage should be individualized according to the response of the patient. The suggested dosage ranges from 25 to 50 mg one to three times daily. Treatment should begin with 25 to 50 mg once daily with subsequent increase in individual dose or frequency according to response. A single daily dose is preferably given in mid-morning or mid-afternoon, according to the patient's eating habits. In an occasional patient it may be desirable to avoid late afternoon administration. Use of benzphetamine hydrochloride is not recommended in individuals under 12 years of age.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29728
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
||
|
DEA NO. |
1228
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
||
|
NDF-RT |
N0000175372
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
||
|
NDF-RT |
N0000175651
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
||
|
LIVERTOX |
97
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
||
|
NDF-RT |
N0000175372
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
||
|
NDF-RT |
N0000175423
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
329
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
1422
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | RxNorm | ||
|
3044
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545985
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
3294
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
m2391
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB05748MIG
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
DB00865
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
978
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
0M3S43XK27
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
C61647
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
100000086364
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
DTXSID4022656
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
156-08-1
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
0M3S43XK27
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY | |||
|
5311017
Created by
admin on Sat Dec 16 18:00:58 GMT 2023 , Edited by admin on Sat Dec 16 18:00:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)